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This study aimed to investigate antimicrobial resistance and molecular epidemiology of
extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (E. coli) isolated from
outpatients in town hospitals of Shandong province, China. Antimicrobial susceptibility
of ESBL-producing E. coli was tested using the disk diffusion and resistance genes
encoding for β-lactamases (blaTEM, blaCTXM, and blaSHV) were detected by polymerase
chain reaction (PCR). Multilocus sequence typing (ST) of ESBL-producing E. coli was
analyzed in this study. Our results showed that of 320 E. coli isolates, 201 carried
ESBL genes (201/320, 62.8%), and these isolates all carried blaCTX-M genes, the most
common being blaCTX-M-14 (116/201, 57.7%), followed by blaCTX-M-55 (47/201, 23.4%)
and blaCTX-M-15 (31/201, 15.4%). ESBL-producing E. coli exhibited highly resistant to
penicillin derivatives, fluoroquinolones, folate pathway inhibitors, and third-generation
cephalosporins, but no carbapenem-resistant isolates were found in this study. Forty-two
STs were found among the 201 ESBL-producing E. coli, and the most common ST was
ST131 (27/201, 13.4%), followed by ST405 (19/201, 9.5%) and ST69 (15/201, 7.5%).
Taken together, a high isolation rate of ESBL-producing E. coli (62.8%) was found among
outpatients in town hospitals. blaCTX-M gene was most dominant and was composed of
a variety of subtypes. No dominant ST was detected among ESBL-producing E. coli,
indicating that these ESBL-producing E. coli isolates derive from different clones.
Keywords: outpatient, antimicrobial resistance, ESBL, ST, town hospital
INTRODUCTION
Beta-lactam antimicrobials are first line anti-bacterial infection drugs for humans due to their
high potency, broad anti-bacterial spectrum, and minimal side effects. They are widely used
in the treatment of various infections, such as those of the lungs, urinary tract, and the
bloodstream. However, widespread use of antibiotics has intensified the problem of antibiotic
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resistance in bacteria (Paterson and Bonomo, 2005; Biedenbach
et al., 2014; D’Angelo et al., 2016). The production of
extended-spectrum beta-lactamases (ESBLs) is an important
mechanism of antimicrobial resistance in Enterobacteriaceae,
especially Escherichia coli (E. coli) and Klebsiella pneumoniae
(K. pneumoniae), and the enzyme can hydrolyze penicillin,
cephalosporin, and monocyclic amide antibiotics, but its activity
is usually inhibited by beta-lactamase inhibitors, such as
sulbactam, clavulanic acid, and tazobactam (Bush et al., 1995;
Bradford, 2001).
Currently, over hundreds of ESBLs have been identified; the
most prevalent genotypes are blaTEM, blaSHV, and blaCTX−M.
Within the past decade, the genotype blaCTX−M has rapidly
increased and is now widely found in clinically isolated E.
coli across the world (Paterson and Bonomo, 2005; Livermore
et al., 2007). In practice, blaCTX−M genes have already become
the major ESBL genotype in American, European, and Asian
countries (Pitout et al., 2005; Livermore et al., 2007; Ben-Ami
et al., 2009; Zhang et al., 2014). Emergence of community-
associated infections caused by ESBL-producing E. coli has been
reported in Europe and the United States (Ben-Ami et al.,
2009). Moreover, relevant studies from Oceania, Asia, and South
America have also reported that ESBL-positive E. coli are the
key pathogens in community-onset infections (Baas and Ahmad,
2001; Bell et al., 2002; Munday et al., 2004; da Silva Dias et al.,
2008; Baurin et al., 2009; Rawat et al., 2013).
Numerous studies in China have already demonstrated that
ESBL-producing E. coli in tertiary and county hospitals is
becoming an epidemic (Xiao et al., 2011, 2012, 2013; Zhang et al.,
2014; Liu et al., 2015). Previous studies that monitored infections
in tertiary hospitals of China indicated that the prevalence
of ESBL-producing E. coli was rapidly on the rise, increasing
from an ESBL-positive rate of <20% in 2000 to 72.2% in 2011
(Xiao et al., 2011, 2012, 2013). A similar study that examined
infections in county hospitals across China also reported an
ESBL-positive rate of up to 46.5% in E. coli (Zhang et al.,
2014). However, these studies were focused on city hospitals, and
there are very few reports that have examined ESBL-producing
E. coli in town hospitals of rural areas in China. Therefore,
this study was undertaken to investigate drug-resistance and
molecular epidemiology of ESBL-producing E. coli isolated from
outpatients in town hospitals of Shandong province, in order to
provide comprehensive and reliable epidemiological information
for preventing dissemination of resistance genes.
MATERIALS AND METHODS
Ethics Statement
This study was in compliance with the various requirements of
the Research Ethics Committee of Taishan Medical University
(Permit No.: TSMC20141012). All participants signed an
informed consent.
Sample Collection
Sputum and urine samples of outpatients were collected from
15 town hospitals across three regions of the Shandong province
(five hospitals per region from October 2014 to September 2015),
for E. coli isolation (Figure 1). The outpatients were selected
according to the following three conditions: (1) they had not
stayed at the hospital within the past 3 months, (2) they had no
long-term intubation, and (3) they had not taken antimicrobial
medication for over 72 h before treatment.
Isolation and Identification of E. coli
Samples were transported back to the lab on ice within 6–10 h
of collection, for E. coli isolation and identification. Samples were
inoculated ontoMacConkey agar plates using sterile cotton swabs
and were incubated overnight at 37◦C in aerobic conditions. Five
single red colonies from each patient sample were selected for
further colony purification, and the colonies were subsequently
identified using conventional biochemical methods and API20
assays (bioMérieux, Durham, NC, USA). All positively identified
E. coli strains (one strain per patient) were stored at −80◦C in
Luria-Bertani (LB) broth containing 30% glycerol.
Antimicrobial Susceptibility and ESBL
Phenotypic Confirmatory Tests
E. coli susceptibility to 17 antibiotics, including ampicillin,
piperacillin, ampicillin-sulbactam, piperacillin-tazobactam,
cefotaxime, cefriaxone, cefuroxime, cefepime, ceftazidime,
aztreonam, imipenem, meropenem, amikacin, gentamicin,
ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole,
was tested using disk diffusion. All drug susceptibility testing
were performed in accordance with the CLSI 2014 criteria
(Clinical Laboratory Standards Institute, 2014). E. coli
ATCC25922 and K. pneumoniae ATCC700603 were used
as quality control strains.
ESBL phenotypic confirmatory test was performed on
E. coli using the double-disc synergy procedure with paper
disks that contained ceftazidime and cefotaxime alone, or
in combination with clavulanic acid (30 µg ceftazidime,
30/10µg ceftazidime/clavulanic acid, 30µg cefotaxime, 30/10µg
cefotaxime/clavulanic acid) (Oxoid Limited, UK; Clinical
Laboratory Standards Institute, 2014).
Bacterial DNA Extraction
Single colonies of ESBL-producing E. coli were inoculated into
LB media and cultured overnight at 37◦C with 220 rpm shaking.
Bacterial culture (1mL) was transferred to an Eppendorf tube,
centrifuged at 12,000 rpm for 5min, before the pellet was
resuspended in 60µl of sterile ultrapure water. The solution was
then placed in boiling water for 10min, immediately transferred
to an ice bath for 5 min, and centrifuged at 12,000 rpm for 5min
to obtain the extracted bacterial DNA in the supernatant.
Detection of Beta-Lactamase Gene by PCR
Polymerase chain reaction (PCR) amplification for the beta-
lactamase genes (TEM, SHV, and CTX-M) were carried out
as previously described (Yu et al., 2007; Dallenne et al.,
2010; Sun et al., 2010; Zhang et al., 2011, 2014). The PCR
products were sequenced following purification, and ESBL
genotype was determined by comparing to GenBank sequences
(http://www.ncbi.nlm.nih.gov/BLAST).
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FIGURE 1 | Sampling sites in this study. (A): The enlarged map of Shandong province, in which sampling sites in three administrative districts was marked. (B):
The location of Shandong province was highlighted in China.
MLST
Multilocus sequence typing of the ESBL-producing E. coli
was performed according to the experimental procedures on
the Environmental Research Institute, University College Cork
website (http://mlst.ucc.ie/mlst/dbs/Ecoli; Lau et al., 2008a). The
E. coli strains were grouped according to the eBURST algorithm
based on their allelic properties, where strains with the same six
out of seven alleles were assigned to the same group (Feil et al.,
2004).
Statistical Analysis
Statistical analysis was performed using SAS 8.2 (SAS
Institute, Cary, NC, USA). Continuous variables and
categorical variables were compared using the Student’s t-
test and chi-squared test or Fisher’s exact test, respectively.
A two-tailed P < 0.05 was considered to be statistically
significant.
RESULTS
Outpatient Demographics
A total of 320 outpatients were recruited in this study,
including 110 from Yantai (YT), 90 from Dezhou (DZ), and
120 from Linyi (LY). Among 320 outpatients aged 10–85
years, there were 32 between 10 and 18 years of age (10.0%),
161 between 19 and 45 years (50.3%), 107 between 46 and
65 years (33.4%), and 20 over 65 years (6.3%). There were
more male (185/320, 57.8%) than female (135/320, 42.2%)
outpatients.
Isolation and Identification of E. coli
A total of 320 E. coli isolates were recovered, comprising 231
isolated from urine (72.2%) and 89 (27.8%) from sputum.
Among these 320 E. coli, 201 carried ESBL genes (201/320,
62.8%), including 67 (67/110, 60.9%), 79 (79/120, 65.8%), and
55(55/90, 61.1%) isolates from YT, LY, and DZ, respectively.
The isolation rates of ESBL-producing E. coli among three
regions did not differ significantly (P > 0.05), but the isolation
rate of ESBL-producing E. coli in urine (170/231, 73.6%)
was significantly higher than that in sputum (31/89, 34.8%;
P < 0.05).
Antimicrobial Resistance Characteristics
All of the 320 E. coli were susceptible to imipenem
and meropenem, and showed high resistance rates to
ampicillin (269/320, 84.1%), piperacillin (251/320, 78.4%),
ciprofloxacin (238/320, 74.4%), levofloxacin (236/320,
73.8%), trimethoprim-sulfamethoxazole (230/320, 71.9%),
gentamicin (222/320, 69.4%), cefotaxime (216/320, 67.5%),
ceftriaxone (209/320, 65.3%), and cefuroxime (206/320,
64.4%). By contrast, these isolates exhibited low resistance
rates to piperacillin/tazobactam (8/320, 2.5%), amikacin
(8/320, 2.5%), ceftazidime (76/320, 23.8%), and cefepime
(78/320, 24.4%). In addition, ESBL-producing E. coli showed
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TABLE 1 | Rates of antimicrobial resistance among E. coli isolates.
Antimicrobial agents No. of isolates (%) P
Total (n = 320) ESBL (n = 201) Non-ESBL (n = 119)
Penicillin derivatives AMP 269 (84.1) 201 (100.0) 68 (57.1) <0.0001
PRL 251 (78.4) 201 (100.0) 50 (42.0) <0.0001
β-Lactam/β-lactamase inhititor combinations SAM 126 (39.4) 112 (55.7) 14 (11.8) <0.0001
TZP 8 (2.5) 5 (2.5) 3 (2.5) –
Cephalosporins CRO 209 (65.3) 192 (95.5) 17 (14.3) <0.0001
CXM 206 (64.4) 195 (97.0) 11 (9.2) <0.0001
CEF 78 (24.4) 75 (37.3) 3 (2.5) <0.0001
CTX 216 (67.5) 198 (98.5) 18 (15.1) <0.0001
CAZ 76 (23.8) 72 (35.8) 4 (3.4) <0.0001
Monobactams ATM 98 (30.6) 95 (47.3) 3 (2.5) <0.0001
Carbapenems IPM 0 (0) 0 (0) 0 (0) –
MEM 0 (0) 0 (0) 0 (0) –
Amimoglycosides AK 8 (2.5) 8 (4.0) 0 (0) <0.0001
GM 222 (69.4) 141 (70.1) 81 (68.1) >0.05
Fluoroquinolones CIP 238 (74.4) 192 (95.5) 46 (38.7) <0.0001
LEV 236 (73.8) 191 (95.0) 45 (37.8) <0.0001
Folate pathway inhibitors SXT 230 (71.9) 190 (94.5) 40 (33.6) <0.0001
AMP, ampicillin; PRL, piperacillin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; CTX, cefotaxime; CRO, cefriaxone; CXM, cefuroxime; CEF, cefepime; CAZ, ceftazidime; ATM,
aztreonam; IPM, imipenem; MEM, meropenem; AK, amikacin; GM, gentamicin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim-sulfamethoxazole.
TABLE 2 | ESBL genes in 201 ESBL-positive E. coli isolates from three administrative districts.
Types of ESBL No. of isolates (%) P
Total YT DE LY
ESBL 201 (100.0) 67 (100.0) 55 (100.0) 79 (100.0) –
CTX-M 201 (100.0) 67 (100.0) 55 (100.0) 79 (100.0) –
CTX-M-14 116 (57.7) 40 (59.7) 28 (50.9) 48 (60.8) >0.05
CTX-M-55 47 (23.4) 15 (22.4) 12 (21.8) 20 (25.3) >0.05
CTX-M-15 31 (15.4) 10 (14.9) 8 (14.5) 13 (16.5) >0.05
CTX-M-1 1 (0.5) 0 (0.0) 0 (0.0) 1 (1.3) –
CTX-M-3 1 (0.5) 0 (0.0) 0 (0.0) 1 (1.3) –
CTX-M-24 1 (0.5) 1 (1.3) 0 (0.0) 0 (0.0) –
CTX-M-27 1 (0.5) 1 (1.3) 0 (0.0) 0 (0.0) –
CTX-M-65 1 (0.5) 0 (0.0)1 (1.3) 1 (1.3) 0 (0.0) –
CTX-M-79 1 (0.5) 0 (0.0) 0 (0.0) 1 (1.3) –
CTX-M-101 1 (0.5) 0 (0.0) 0 (0.0) 1 (1.3) –
YT, Yantai; DE, Dezhou; LY, Linyi.
significantly higher resistance rates to most antibiotics
compared with those of non-ESBL-producing E. coli (P <
0.0001). However, the low resistance rate against piperacillin-
tazobactam and high resistance rate to gentamicin in the
two populations did not differ significantly (P > 0.05;
Table 1).
ESBL Gene Characteristics
All of the 201 ESBL-producing E. coli strains carried blaCTX-M
genes, with the most common being blaCTX-M-14 (116/201,
57.7%), followed by blaCTX-M-55 (47/201, 23.4%) and
blaCTX-M-15 (31/201, 15.4%). Additionally, 122 of the 201
ESBL-producing E. coli strains simultaneously carried blaTEM-1
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FIGURE 2 | Minimum spanning tree constructed based on the MLST profiles of ESBL-producing E. coli. There were 23 singletons, 5 groups (group1: ST58,
ST155; group2: ST93, ST373; group3: ST23, ST410; group4: ST2003, ST38, ST1177; group5: ST648, ST5005), and 1 clonal complex (ST617, ST167, ST10, ST44,
ST218, ST744, ST697, ST4704), which was radial. The blue dot in it indicated putative founder. The area of each black circle corresponded to the prevalence of the
ST in the MLST data of this study.
genes. blaSHV genes were not detected in this study. There was no
significant difference in the prevalence of blaCTX-M genes among
the ESBL-producing E. coli isolated from the three regions (P >
0.05; Table 2).
Multilocus Sequence Typing of
ESBL-Producing E. coli
A total of 42 different STs were found, which were grouped in
5 non-overlapping groups, 1 clonal complex, and 23 singletons
(Figure 2). The most common ST were ST131 (27/201, 13.4%),
followed by ST405 (19/201, 9.5%) and ST69 (15/201, 7.5%). There
were 27 ST131 detected from town hospitals across the three
regions, including 17 strains that were blaCTX-M-14-positive,
4 strains that were blaCTX-M-15-positive, 5 strains that were
blaCTX-M-55-positive, and 1 strain that carried blaCTX-M-3 gene
(Table 3).
DISCUSSION
To our best knowledge, this study was the first time to investigate
drug resistance and molecular characteristics of ESBL-producing
E. coli from outpatients in town hospitals of Shandong province,
China. The isolation rate of ESBL-producing E. coli in our
study was 62.8%, which was similar with Zhao’s (62.5%) and
Wang’s (67.8%) results conducted in Shanghai, China (Zhao et al.,
2015; Wang et al., 2016), but higher than those reported in
Argentina (18.1%), Mexico (48.4%), Chile (23.8%), and Brazil
(12.8%; Gales et al., 2012). All ESBL-producing E. coli from these
three regions carried blaCTX-M genes, which was composed of 10
genotypes including blaCTX-M-1,-3,-14,-15,-24,-27,-55,-65,-79,and-101.
This indicates that ESBL-producing E. coli from Shandong
province have diverse CTX-M genotypes, and similar results were
also found in the tertiary and county hospitals of China (Zhang
et al., 2014; Zhao et al., 2015; Wang et al., 2016).
E. coli isolated in this study were found to be highly resistant to
penicillin derivatives, fluoroquinolone, folate pathway inhibitors,
and third generation cephalosporins, but were 100% susceptible
to imipenem and meropenem. In addition, these isolates
displayed low resistance to amikacin, piperacillin/tazobactam,
ceftazidime, and cefepime. The antibiotics to which the E. coli
was found to be highly resistant are common medications used
in Shandong town hospitals, and therefore our findings should
caution clinicians for the rational use of antibiotics.
We found that blaCTX-M-14 was the most prevalent genotype
of ESBL-producing E. coli in Shandong town hospitals, followed
by blaCTX-M-55 and blaCTX-M-15, which is consistent with
findings reported in Chinese county hospitals between 2010 and
2011 (Zhang et al., 2014), as well as in 3 Shanghai hospital
studies between 2011 and 2013 (Zhao et al., 2015). CTX-M-55
genotype, which only has 1 amino acid site mutation (Ala-77-
Val) compared to CTX-M-15 genotype, was first discovered in
clinically isolated E. coli and K. pneumoniae from Thailand in
Frontiers in Microbiology | www.frontiersin.org 5 January 2017 | Volume 8 | Article 63
Miao et al. ESBL-Producing E. coli within Town Hospitals
TABLE 3 | Genotypes in MLST of 201 ESBL-producing E.coli isolates in
this study.
ST Total
number
ESBL genes (number)
CTX-M-14 CTX-M-15 CTX-M-55 Others
ST131 27 17 4 5 CTX-M-3 (1)
ST405 19 15 2 2
ST69 15 9 3 3
ST95 12 8 1 3
ST38 11 8 1 2
ST648 10 7 2 1
ST617 10 7 1 2
ST10 10 4 3 2 CTX-M-1 (1)
ST393 10 8 1 1
ST73 10 6 2 2
ST2003 10 6 2 2
ST23 7 1 2 4
ST44 4 2 1 1
ST58 4 1 2 CTX-M-24 (1)
ST68 4 1 1 2
ST93 4 1 2 1
ST155 4 1 1 2
ST162 2 1 1
ST167 2 1 1
ST218 2 1
ST373 2 2
ST410 2 1 1
ST450 1 2
ST602 1 1
ST697 1 1
ST744 1 1
ST746 1 CTX-M-27 (1)
ST847 1 1
ST998 1 1
ST1177 1 1
ST1193 1 1
ST1304 1 CTX-M-79 (1)
ST1642 1 1
ST2077 1 1
ST2973 1 1
ST3902 1 CTX-M-65 (1)
ST4038 1 1
ST4456 1 1
ST4704 1 1
ST4995 1 1
ST5005 1 1
ST5006 1 CTX-M-101 (1)
201 116 31 47 7
2007 (Kiratisin et al., 2007), and was subsequently detected in
Salmonella in China, US, Korea, and Switzerland (Shi et al., 2009;
Sjölund-Karlsson et al., 2011). At present, CTX-M-55 genotype
is frequently detected in ESBL-producing E. coli that originates
from animals (Dinubile et al., 2005; Ma et al., 2012; Zheng
et al., 2012; Zurfluh et al., 2013; Li et al., 2016). In China,
two nationwide breeding farm studies have shown that CTX-
M-55 was, respectively, the second (26.1%, 29/111) and third
(18.5%, 10/54) most frequently detected ESBL gene (Li et al.,
2010; Zheng et al., 2012). These findings demonstrated that
blaCTX-M-55 gene may have already been passed from animals
to humans through the food chain. The subjects of this study
were outpatients from rural town hospitals. Since residents from
these regions have greater exposure to food animals and breeding
farms, compared to those living in the cities, the chance of
transmission of drug-resistant bacteria from animals to humans
is therefore increased. However, the transmission mechanism
of drug-resistant bacteria from animals to humans is currently
unclear, and further studies are required to elucidate this process.
Additionally, it is an interesting finding that the resistance to
cefotaxime and ceftriaxone is not 100% while only CTX-M-type
ESBLs were found in this study, which is needed to be further
studied.
Although ST131 was the most common ST among the 201
ESBL-producing E. coli strains, it only accounted for 13.4%
of the total ST. Similarly, some recent nationwide studies
in tertiary and county hospitals have also shown that ST131
was found in 9.6% and 12.7% of ESBL-producing E. coli,
respectively, indicating that no predominant ESBL-producing
E. coli ST epidemic was found in China (Cao et al., 2011;
Zhang et al., 2014). In contrast, the percentage of ST131
ESBL-producing E. coli in many European and American
countries is far greater than that in China. For example, a
community infection study in U.S showed that 53% of ESBL
gene CTX-M-carrying E. coli were ST131 (Pitout et al., 2005).
Another community infection study in the U.K also reported
that ST131 comprised 64% of the cephalosporin-resistant E.
coli (Lau et al., 2008b). Furthermore, a similar community
infection study in Belgium between 2006 and 2007 showed
that 64% of CTX-M-15-carrying E. coli was also ST131 (Smet
et al., 2010). Of note, some sequence types found in this
work belong to known international clonal complexes, such
as ST131, ST393, and ST405 (Wirth et al., 2006; Hrabák
et al., 2009). These international clonal complexes have been
described as E. coli clones disseminating on a global scale
(Coque et al., 2008; Nicolas-Chanoine et al., 2008; Literacka et al.,
2009; Lee et al., 2010).
CONCLUSIONS
Taken together, These findings demonstrated the
high isolation rate of ESBL-producing E. coli (62.8%)
detected in outpatients in town hospitals, China,
and the blaCTX-M gene was most dominant and was
composed of a variety of subtypes. More importantly,
this study spotlights the necessity to carry out long-
term surveillance of ESBL-producing E. coli in
hospital environments, especially in underdeveloped
areas.
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